Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder. [electronic resource]
- Clinical cancer research : an official journal of the American Association for Cancer Research Sep 2001
- 2840-53 p. digital
Publication Type: Journal Article; Research Support, U.S. Gov't, P.H.S.
1078-0432
Adult Aged Animals Antineoplastic Agents, Phytogenic--therapeutic use Biopsy Blood Vessels--drug effects Blotting, Northern Cadherins--analysis Carcinoma, Transitional Cell--drug therapy Cell Movement--drug effects Collagen Collagenases--drug effects Dose-Response Relationship, Drug Drug Combinations Drug Synergism Endothelial Growth Factors--genetics Female Fibroblast Growth Factor 2--genetics Follow-Up Studies Gene Expression Regulation, Neoplastic--drug effects Humans In Situ Hybridization Interferon-alpha--therapeutic use Interleukin-8--genetics Laminin Lymphokines--genetics Male Matrix Metalloproteinase 9--analysis Mice Mice, Inbred BALB C Mice, Nude Middle Aged Neoplasm Invasiveness Neoplasm Metastasis--pathology Neoplasm Staging Neovascularization, Pathologic--prevention & control Paclitaxel--therapeutic use Prognosis Proteoglycans RNA, Messenger--drug effects Tumor Cells, Cultured Urinary Bladder--chemistry Urinary Bladder Neoplasms--drug therapy Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors Xenograft Model Antitumor Assays